|1.||Avila A, Alejandra: 1 article (01/2006)|
|2.||Gunn, Ronald D: 1 article (01/2006)|
|3.||Iñíguez V, Germán: 1 article (01/2006)|
|4.||Román R, Rossana: 1 article (01/2006)|
|5.||Barrera P, Alvaro: 1 article (01/2006)|
|6.||Mericq G, Verónica: 1 article (01/2006)|
|7.||Salazar C, Teresa: 1 article (01/2006)|
|8.||Fuentes G, Ariel: 1 article (01/2006)|
|9.||Cassorla G, Fernando: 1 article (01/2006)|
|10.||Kemp, Stephen F: 1 article (04/2005)|
|1.||Type 1 Diabetes Mellitus (Autoimmune Diabetes)
|2.||Laron Syndrome (Syndrome, Laron)
04/01/2003 - "SomatoKine, a recombinant fusion of insulin-like growth factor-1 and its binding protein, BP-3, is being developed by Insmed (formerly Celtrix Pharmaceuticals) for the potential treatment of growth hormone insensitivity syndrome (GHIS), and as a potential injectable insulin sensitizer for the management of type 1 and type 2 diabetes in patients who are less sensitive to insulin therapy. "
|3.||Hypoglycemia (Reactive Hypoglycemia)
04/01/2005 - "SomatoKine appears to have a longer half-life in patients with GHIS than unbound IGF-I and fewer adverse events (including hypoglycemia) have been reported when administered to patients with diabetes."
04/01/2005 - "SomatoKine was developed to prolong the half-life and to counteract acute adverse events (particularly hypoglycemia) associated with IGF-I administration. "
04/01/2005 - "SomatoKine: is there a use in treating growth disorders?"
|5.||Type 2 Diabetes Mellitus (MODY)
|2.||Insulin-Like Growth Factor I (IGF-1)
|3.||Insulin-Like Growth Factor Binding Protein 3
|4.||Carrier Proteins (Binding Protein)